NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 110 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $709,000 | -84.1% | 55,294 | -81.1% | 0.00% | -84.6% |
| Q1 2022 | $4,450,000 | -13.9% | 291,801 | 0.0% | 0.03% | +4.0% |
| Q4 2021 | $5,168,000 | -15.7% | 291,801 | 0.0% | 0.02% | -7.4% |
| Q3 2021 | $6,134,000 | +6.6% | 291,801 | 0.0% | 0.03% | +8.0% |
| Q2 2021 | $5,754,000 | -32.2% | 291,801 | 0.0% | 0.02% | -32.4% |
| Q1 2021 | $8,483,000 | +162.6% | 291,801 | +173.7% | 0.04% | +208.3% |
| Q4 2020 | $3,230,000 | +71.9% | 106,616 | -9.7% | 0.01% | +50.0% |
| Q3 2020 | $1,879,000 | -23.5% | 118,100 | -5.1% | 0.01% | -27.3% |
| Q2 2020 | $2,456,000 | -20.3% | 124,400 | -50.2% | 0.01% | -42.1% |
| Q1 2020 | $3,083,000 | -33.3% | 250,000 | 0.0% | 0.02% | -24.0% |
| Q4 2019 | $4,623,000 | +33.5% | 250,000 | 0.0% | 0.02% | +4.2% |
| Q3 2019 | $3,463,000 | -5.4% | 250,000 | 0.0% | 0.02% | -4.0% |
| Q2 2019 | $3,660,000 | – | 250,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $447,565,000 | 42.88% |
| Greenspring Associates, LLC | 1,573,357 | $45,737,000 | 36.38% |
| Ponoi II Management, LLC | 1,298,908 | $37,759,000 | 28.92% |
| Ponoi Management, LLC | 1,298,908 | $37,759,000 | 22.21% |
| Euclidean Capital LLC | 1,493,349 | $43,412,000 | 14.52% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $109,497,000 | 10.53% |
| Aquilo Capital Management, LLC | 1,124,237 | $32,682,000 | 5.91% |
| Octagon Capital Advisors LP | 200,000 | $5,814,000 | 2.19% |
| Redmile Group, LLC | 2,751,815 | $79,995,000 | 1.13% |
| Hennion & Walsh Asset Management, Inc. | 259,841 | $7,554,000 | 0.45% |